The deal reinforces GSK’s leadership in respiratory care and builds upon the company’s expanding COPD portfolio
The company's net income attributable to equity holders dropped to €2.80 billion from €2.82 billion last year
Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio
Air Liquide will provide care for people living with respiratory diseases such as chronic obstructive pulmonary disease (COPD) and sleep apnea
Includes new $1.2 billion investment in manufacturing facilities, AI and advanced digital technologies, creating hundreds of highly skilled U.S. jobs
The company’s acquisition of a 51 per cent stake in Saarathi Healthcare earlier this financial year boosted growth
Pfizer's vaccine helps protect against clinically relevant 20 serotypes responsible for a majority of invasive and non-invasive pneumococcal disease
Trixeo is the first pMDI medicine in AstraZeneca’s portfolio to use the near-zero GWP propellant
GSK and Hengrui Pharma enter agreements to develop up to 12 innovative medicines across Respiratory, Immunology & Inflammation and Oncology
The phase III ARNASA study did not meet the primary endpoint of a statistically significant reduction in the AER at 52 weeks
Subscribe To Our Newsletter & Stay Updated
